Measurement Error in Early Alzheimer’s Trials

Where early Alzheimer’s trials are most exposed

In early Alzheimer’s disease, cognitive decline progresses slowly and unevenly. Primary endpoints depend on repeated cognitive assessments performed over many months, sometimes years, across multiple sites and countries. Small differences in how assessments are conducted or interpreted can accumulate over time and have a meaningful impact on trial results.

When the expected difference between treatment and placebo is small, the margin for error is narrow. Under these conditions, data quality becomes just as critical as protocol design.

Most clinical outcome assessments in Alzheimer’s disease are represented by validated questionnaires that include information from patients, care partners and clinicians, collectively assessing a therapeutic effect. These questionnaires, whether they are measures from individual tests, or composites based on larger neuropsychological batteries, are indirect measures of a latent trait hypothesised to represent underlying cognition and are therefore subject to measurement error.

There are three main confounders that generate measurement error and can contribute to the alteration of trial endpoints: Rater drift, practice effects and assessment variability.

Rater drift: subtle, common, and often underestimated

Rater drift is the tendency for human observers or assessors to change their scoring standards over time, which often leads to decreased reliability and accuracy in assessments. It develops gradually, it is rarely intentional and usually reflects normal human behavior, increasing familiarity with the scale, adapting to patients, or slight shifts in how scoring rules are applied over time.

From a medical monitoring perspective, the concern is not a single incorrect assessment, but the slow loss of longitudinal consistency. Scores may remain within acceptable ranges, while the underlying scoring behavior changes. If this drift is not identified early, it increases variability and reduces confidence in the primary endpoint.

In order to overcome this issue, there are a few useful approaches:

• Conduct regular, ongoing training
• Hold re-calibration sessions
• Monitoring inter-rater reliability

Effective rater training should extend beyond theory by integrating didactic instruction with the analysis of real-world data on administration and scoring errors.

One step further is to specifically train the medical monitors who will perform central data review by providing them with dedicated materials regarding common rater errors.

This is one of the reasons why traditional site monitoring alone is often insufficient in cognition-driven trials.

Practice effects and the illusion of stability

Practice effects are a well-known feature of cognitive testing, but their impact is often underestimated in early Alzheimer’s trials. Repeated exposure to the same assessments can lead to improved performance unrelated to disease biology or treatment effect.

Clinically, this often appears as unexpected stability or improvement in placebo-treated patients during the first months of a study. While reassuring at first glance, this phenomenon reduces separation between treatment arms and weakens the ability to detect a true effect.

Once practice effects are embedded in the data, they cannot be undone.

Current strategies for reducing the impact of practice effects in clinical trials include:

• Use of alternate test forms
• Limiting analyses to subgroups based on the presence or absence of practice effects
• Incorporating a single-blind placebo run-in period into the study design to “wash out” practice effects prior to randomisation

Variability across sites and regions

Global enrollment is essential in Alzheimer’s disease, but it comes with increased variability. Differences in language, cultural context, rater experience, and patient characteristics all influence cognitive assessments.

From medical monitoring review, it is not uncommon to see that a limited number of sites or raters contribute disproportionately to overall variability. When pooled across the study, this noise can obscure meaningful trends observed elsewhere.

Recently, substantial improvements in available algorithms and advances in specialised statistical software have greatly reduced barriers to implementing Bayesian models. Current statistical methodologies now use multilevel measurement error models to account for measurement error when analysing the proportion of variance explained in cognitive outcomes.

Bayesian models that use alternative methods to estimate explained variance can accommodate the variability observed in Alzheimer’s disease trials; however, this variability must be considered when interpreting the final conclusions. Managing variability is therefore not a statistical exercise at the end of the trial, but a clinical responsibility throughout its conduct.

What medical monitoring adds in practice

In early Alzheimer’s disease, medical monitoring goes beyond safety surveillance. It involves continuous clinical oversight of how data are generated and interpreted.

In practice, this includes:

• Reviewing cognitive data longitudinally to assess consistency over time
• Identifying unexpected patterns at the site or rater level
• Discussing emerging risks with clinical and operational teams
• Supporting timely, proportionate corrective actions while preserving trial integrity

The objective is not to intervene excessively, but to ensure that the trial remains capable of answering its primary question.

Why this matters to sponsors

Alzheimer’s disease programs require significant investment and long-term commitment. When a trial fails because the signal is obscured rather than absent, the consequences are substantial, both scientifically and strategically. Sponsors increasingly value partners who understand these risks from experience and who can help protect data interpretability while the study is still ongoing. In cognition-driven trials, this role is central to informed decision-making.

---